Laurent Greillier Selected Research

Platinum

5/2024	Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
11/2023	Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
1/2023	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
1/2022	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
8/2021	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
1/2021	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
1/2020	Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
1/2019	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurent Greillier Research Topics

Disease

46	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 04/2004
42	Neoplasms (Cancer) 05/2024 - 01/2008
15	Malignant Mesothelioma 01/2022 - 11/2007
13	Lung Neoplasms (Lung Cancer) 05/2024 - 03/2012
11	Mesothelioma 02/2024 - 01/2008
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2024 - 11/2017
6	Brain Neoplasms (Brain Tumor) 03/2024 - 11/2017
6	Neoplasm Metastasis (Metastasis) 11/2023 - 11/2010
3	Disease Progression 01/2023 - 12/2018
3	Thymoma (Thymic Carcinoma) 01/2022 - 01/2016
3	Neutropenia 01/2020 - 11/2017
2	Frailty 12/2021 - 12/2020
2	Adenocarcinoma 11/2021 - 12/2014
2	Encephalitis (Encephalitis, Rasmussen) 01/2021 - 01/2019
2	Carcinoma (Carcinomatosis) 01/2021 - 11/2018
2	Febrile Neutropenia 01/2020 - 11/2017
2	Asthenia 01/2020 - 01/2019
2	Fatigue 01/2019 - 06/2017
2	Pleural Effusion (Pleural Effusions) 04/2016 - 01/2008
1	Autoimmune Diseases (Autoimmune Disease) 04/2024
1	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2024
1	Microsatellite Instability 02/2024
1	Weight Loss (Weight Reduction) 05/2023
1	Oncogene Addiction 01/2023
1	Neuralgia (Stump Neuralgia) 01/2023
1	Cognitive Dysfunction 05/2022
1	COVID-19 01/2022
1	Malnutrition (Nutritional Deficiencies) 12/2021
1	Edema (Dropsy) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Heart Failure 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Sepsis (Septicemia) 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2019
1	Massive Hepatic Necrosis 01/2019
1	Adenocarcinoma of Lung 01/2019

Drug/Important Bio-Agent (IBA)

16	Pemetrexed (MTA)FDA Link 11/2023 - 03/2009
10	Cisplatin (Platino)FDA LinkGeneric 11/2023 - 04/2011
9	Immune Checkpoint InhibitorsIBA 05/2024 - 12/2018
9	Bevacizumab (Avastin)FDA Link 01/2023 - 04/2016
8	PlatinumIBA 05/2024 - 01/2019
8	pembrolizumabIBA 03/2024 - 11/2019
8	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2008
5	Carboplatin (JM8)FDA LinkGeneric 11/2023 - 01/2020
5	LigandsIBA 10/2023 - 01/2019
5	IpilimumabIBA 01/2022 - 03/2012
5	NivolumabIBA 01/2022 - 01/2019
4	B7-H1 AntigenIBA 05/2024 - 01/2019
4	atezolizumabIBA 11/2023 - 01/2019
4	AsbestosIBA 04/2016 - 01/2008
3	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2024 - 10/2023
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022 - 07/2017
2	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 05/2024 - 01/2020
2	Gefitinib (Iressa)FDA Link 02/2024 - 06/2005
2	osimertinibIBA 02/2024 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 01/2024 - 01/2023
2	Tyrosine Kinase InhibitorsIBA 01/2023 - 02/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 04/2016
2	Docetaxel (Taxotere)FDA Link 01/2022 - 11/2021
2	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 12/2021 - 12/2020
2	nintedanibIBA 11/2021 - 11/2017
2	Circulating Tumor DNAIBA 01/2021 - 11/2020
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2021 - 01/2020
2	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2008
2	Sunitinib (Sutent)FDA Link 11/2016 - 01/2016
1	ParaffinIBA 02/2024
1	Formaldehyde (Formol)FDA Link 02/2024
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2023
1	AntibodiesIBA 06/2023
1	Analgesics (Analgesic Drugs)IBA 01/2023
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2023
1	Cell-Free Nucleic AcidsIBA 10/2022
1	AmphiregulinIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	VaccinesIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	pertuzumabIBA 01/2022
1	lenvatinibIBA 01/2022
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 12/2020
1	C-Reactive ProteinIBA 12/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 01/2020
1	rovalpituzumab tesirineIBA 12/2019
1	lorlatinibIBA 12/2019
1	trametinibIBA 01/2019
1	alectinibIBA 01/2019
1	Anaplastic Lymphoma KinaseIBA 01/2019

Therapy/Procedure

27	Therapeutics 05/2024 - 11/2007
27	Drug Therapy (Chemotherapy) 05/2024 - 11/2007
6	Immunotherapy 04/2024 - 10/2020
5	Radiotherapy 01/2021 - 11/2007
3	Combination Drug Therapy (Combination Chemotherapy) 10/2023 - 01/2020
2	Chemoradiotherapy 01/2024 - 04/2018
2	Activities of Daily Living (ADL) 05/2022 - 01/2022
2	Precision Medicine 01/2021 - 12/2017
1	Home Nursing (Nursing, Home) 07/2021
1	Cryosurgery 01/2021
1	Ambulatory Care (Outpatient Care) 12/2020
1	Medication Reconciliation 01/2020